Clinical Importance of Central Sensitization and Neuropathic Pain in The Treatment and Follow-Up of Patients with Psoriasis and Psoriatic Arthritis. — CFSMEATLAS
E2 ModeratePreliminaryPEM not requiredCross-SectionalPeer-reviewedMachine draft
Standard · 3 min
Clinical Importance of Central Sensitization and Neuropathic Pain in The Treatment and Follow-Up of Patients with Psoriasis and Psoriatic Arthritis.
Koca, Tuba Tülay, Göğebakan, Hasan, Nazik, Hülya et al. · Indian journal of dermatology · 2026 · DOI
Quick Summary
This study looked at whether people with skin and joint conditions (psoriasis and psoriatic arthritis) experience unusual pain processing in their nervous system, similar to what happens in conditions like fibromyalgia. Researchers found that many patients with these conditions had signs of nervous system sensitization and neuropathic pain (nerve-related pain). The more active their disease was, the more likely they were to have these pain processing problems.
Why It Matters
This research is relevant to ME/CFS patients because central sensitization and neuropathic pain overlap significantly with ME/CFS symptomatology (fatigue, pain, autonomic dysfunction). Understanding how nervous system hyperexcitability connects to chronic disease activity may inform treatment approaches for ME/CFS patients who experience similar pain amplification and autonomic features.
Observed Findings
Central sensitization was present in 68% of psoriasis patients and 35.8% of PsA patients, compared to 63.6% of healthy controls.
Neuropathic pain was detected in 50% of psoriasis patients, 60.4% of PsA patients, and 63.6% of healthy controls.
Chronic fatigue syndrome was reported in 40% of psoriasis patients and 39.6% of PsA patients.
Minimal disease activity (MDA) score showed strong inverse correlation with central sensitization inventory score (beta = -0.534; P < 0.001).
Fibromyalgia syndrome was present in 28.3% of PsA patients and restless leg syndrome in 22% of psoriasis patients.
Inferred Conclusions
Central sensitization and neuropathic pain are frequently comorbid with psoriasis and PsA and should be routinely assessed in patient management.
Disease activity (measured by MDA) is strongly associated with the degree of central sensitization in PsA patients.
Multiple overlapping central sensitization syndromes (fatigue, pain, anxiety, IBS) commonly occur together in these inflammatory conditions and warrant integrated treatment approaches.
Remaining Questions
Why do healthy controls show such high rates of central sensitization (63.6%), and what distinguishes symptomatic from asymptomatic central sensitization?
What This Study Does Not Prove
This study does not prove that central sensitization causes disease activity or vice versa—only that they are statistically associated. The high prevalence of CS in healthy controls (63.6%) raises questions about the specificity of these findings and suggests factors beyond disease pathology contribute to CS. The cross-sectional design cannot establish temporal relationships or determine whether interventions targeting CS would improve patient outcomes.
Tags
Symptom:PainFatigueSensory Sensitivity
Method Flag:Weak Case DefinitionSmall SampleExploratory Only
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Does treating central sensitization independently of the underlying inflammatory disease improve clinical outcomes in psoriasis and PsA?
What is the longitudinal trajectory of central sensitization in relation to disease activity—does it persist after inflammatory control, or does it resolve?
Are specific cytokines or inflammatory markers associated with central sensitization development in these patient populations?